In the present study, we provide the compelling evidence that OAT-1746, a novel and oral small-molecule inhibitor of ARG1/2, affects glioma-microglia interactions in vitro, accumulates in the brain and modulates the TME of murine intracranial gliomas. This evidence concerns the gene ARG1 and central nervous system cancer.